开云app官网登录入口网页版-官方正版

#DKD#

5篇内容 | 1152人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2210060, encodeId=c45a2210060cb, content=<a href='/topic/show?id=5c1d22423c8' target=_blank style='color:#2F92EE;'>#中药#</a> <a href='/topic/show?id=f61b2894204' target=_blank style='color:#2F92EE;'>#免疫#</a> <a href='/topic/show?id=645f8e7207b' target=_blank style='color:#2F92EE;'>#药物学#</a> <a href='/topic/show?id=53c66e0011b' target=_blank style='color:#2F92EE;'>#炎症#</a> <a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a> <a href='/topic/show?id=fe4211553893' target=_blank style='color:#2F92EE;'>#治疗学#</a>, objectTitle=J Ethnopharmacol：中药治疗糖尿病肾病炎症的机制探讨, objectType=article, longId=830318, objectId=c9be83031865, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240615/1718455827735_5610093.jpg, objectUrl=/article/show_article.do?id=c9be83031865, replyNumber=0, likeNumber=80, createdTime=2024-06-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c9be83031865, moduleTitle=J Ethnopharmacol：中药治疗糖尿病肾病炎症的机制探讨, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c9be83031865)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191001, encodeId=9ac5219100168, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=cd1811189937' target=_blank style='color:#2F92EE;'>#DPd#</a>, objectTitle=【EJH】DPd对比DKd治疗达雷妥尤单抗未暴露RRMM的回顾性研究, objectType=article, longId=815866, objectId=05908158664d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=05908158664d, replyNumber=0, likeNumber=128, createdTime=2024-03-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=05908158664d, moduleTitle=【EJH】DPd对比DKd治疗达雷妥尤单抗未暴露RRMM的回顾性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=05908158664d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1545517, encodeId=fb26154551e30, content=<a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a>, objectTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, objectType=article, longId=210971, objectId=aae42109e1a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae42109e1a9, replyNumber=0, likeNumber=101, createdTime=2021-05-10, rootId=0, userName=12498b08m94暂无昵称, userId=773213763478, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae42109e1a9, moduleTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aae42109e1a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545516, encodeId=25a615455160f, content=<a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=117, createdTime=2020-10-30, rootId=0, userName=12498b08m94暂无昵称, userId=773213763478, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545515, encodeId=97541545515c8, content=<a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a>, objectTitle=陈春教授：DKD发病机理研究与药物治疗靶点探索丨CSN2019, objectType=article, longId=179757, objectId=2aa51e975728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2aa51e975728, replyNumber=0, likeNumber=115, createdTime=2019-09-21, rootId=0, userName=12498b08m94暂无昵称, userId=773213763478, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2aa51e975728, moduleTitle=陈春教授：DKD发病机理研究与药物治疗靶点探索丨CSN2019, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2aa51e975728)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545514, encodeId=b6ad1545514c7, content=<a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a>, objectTitle=Blood：达雷木单抗联合卡非佐米/地塞米松（Dkd）为来那度胺难治性多发性骨髓瘤患者带来新的希望, objectType=article, longId=166648, objectId=b66c16664857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b66c16664857, replyNumber=0, likeNumber=93, createdTime=2019-05-24, rootId=0, userName=12498b08m94暂无昵称, userId=773213763478, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b66c16664857, moduleTitle=Blood：达雷木单抗联合卡非佐米/地塞米松（Dkd）为来那度胺难治性多发性骨髓瘤患者带来新的希望, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b66c16664857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1545513, encodeId=dc201545513a1, content=<a href='/topic/show?id=aa77602136' target=_blank style='color:#2F92EE;'>#DKD#</a>, objectTitle=壮士断腕吉利德新药selonsertib舍弃PAH、DKD专注NASH领域研发, objectType=article, longId=80904, objectId=fa9780904d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9780904d9, replyNumber=0, likeNumber=96, createdTime=2016-10-26, rootId=0, userName=12498b08m94暂无昵称, userId=773213763478, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9780904d9, moduleTitle=壮士断腕吉利德新药selonsertib舍弃PAH、DKD专注NASH领域研发, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fa9780904d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

DKD

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#中药# #免疫# #药物学# #炎症# #DKD# #治疗学#

J Ethnopharmacol：中药治疗糖尿病肾病炎症的机制探讨

2024-06-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #DKD# #达雷妥尤单抗# #DPd#

【EJH】DPd对比DKd治疗达雷妥尤单抗未暴露RRMM的回顾性研究

2024-03-04发表于上海

12498b08m94暂无昵称 (审核中...)

前往app查看评论内容

#DKD#

III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点

2021-05-10

12498b08m94暂无昵称 (审核中...)

前往app查看评论内容

#DKD#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2020-10-30

12498b08m94暂无昵称 (审核中...)

前往app查看评论内容

#DKD#

陈春教授：DKD发病机理研究与药物治疗靶点探索丨CSN2019

2019-09-21

12498b08m94暂无昵称 (审核中...)

前往app查看评论内容

#DKD#

Blood：达雷木单抗联合卡非佐米/地塞米松（Dkd）为来那度胺难治性多发性骨髓瘤患者带来新的希望

2019-05-24

12498b08m94暂无昵称 (审核中...)

前往app查看评论内容

#DKD#

壮士断腕吉利德新药selonsertib舍弃PAH、DKD专注NASH领域研发

2016-10-26

科室
- - 订阅+
  - 更多科室
工具
服务